Biocon Share Price Target 2024-2030 Fundamentals & Quarterly Results

Biocon Share Price Target 2024 2025 2026 2027 2028 2029 2030 Fundamentals & Quarterly Results – In 1978, Biocon limited was established and the organization has since then specialized in the research and treatment of various terminal diseases that affect human beings. These include cancer, diabetes among others. As a multinational corporation, their products are available in many different nations around the world.

Latest Update – For the first quarter of FY 24, Biocon Limited made an announcement that its net profit rose by 550.5 percent to ₹659.7 crore from ₹ 101.4 crore during the corresponding period last year.

Biocon Overview

The Biocon Company is actively manufacturing biotechnological products and provides research services.

Also Check Indian Overseas Bank Share Price Target

Biocon Business Profile

Biocon Ltd (Biocon) is a biotechnology company that manufactures drugs. It specializes in research and development of treatments for chronic diseases like cancer, diabetes and auto immune ailments. The company also manufactures active pharmaceutical ingredients (APIs), branded formulations, complex biologics and biosimilars including monoclonal antibodies (MAbs), rh-Insulin, and insulin analogs.

Also Check Apollo Tyres Share Price Target

Some additional services by the company include contract manufacturing, drug licensing, research, and development of small and large molecules for biotechnology as well as pharmaceutical firms around the world. It has a manufacturing facility and R&D center at BioXcell in Malaysia. The company has an operational presence in UK, Ireland, US, Switzerland, UAE and Malaysia. The headquarters is located in Bangalore city of Karnataka state in India.

Also Check Jyoti CNC Share Price Target

Biosimilars

Some additional services by the company include contract manufacturing, drug licensing, research, and development of small and large molecules for biotechnology as well as pharmaceutical firms around the world. It has a manufacturing facility and R&D center at BioXcell in Malaysia. The company has an operational presence in UK, Ireland, US, Switzerland, UAE and Malaysia. The headquarters is located in Bangalore city of Karnataka state in India.

Also Check Cochin Shipyard Share Price Target

Research Services

The research services division of Biocon, Syngene, is listed independently. It provides unified discovery research, development, and manufacturing services across various industries including pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals. It has partnered with 15 of the 20 leading pharmaceutical firms.

Also Check NBCC Share Price Target

Generics

It is the first Indian company among U.S.D FDA approved companies which manufacture Lovastatin that is a fermentation based statin API used for cholesterol reduction. The API portfolio comprises of more than 50 products across different therapeutic areas such as cardiovascular diseases, anti-diabetics, immunosuppressants, oncology high potent API (HPAPI) and some specialty drug molecules. These APIs are provided to over 750 pharmaceutical firms in 75 countries including USA and Europe.

Also Check ZEEL Share Price Target

Novel Biologics

In India, under the brand name ALZUMAb, the company launched Nimotuzumab, the first indigenously produced monoclonal antibody for head and neck cancer, and Itolizumab, the first novel anti-CD6 monoclonal antibody in the world for psoriasis. Bicara Therapeutics (a Boston, USA-based associate) is involved in developing bifunctional antibodies that take advantage of recent progress made in immuno-oncology.

Also Check L&T Finance Share Price Target

Manufacturing Expansion

During the fiscal year 2024, Biocon bought an Oral Solid Dosage production unit from New Jersey USA. The immunosuppressant unit in Vizag is poised for qualification to supply commercial products by the end of FY2025 in India.

Also Check Ambuja Cement Share Price Target

From the year FY24, process validation activities have been completed at the Peptide facility located in Bengaluru for all products to be prepared by this center for future launches as well as conversions. In addition, there are ongoing improvements in synthetic capacity in Hyderabad, non-immune fermentation capacity and Bengaluru has established a new sterile injectable facility.

Also Check BPCL Share Price Target

Biocon Fundamentals & Quarterly Results

Also Check HBL Share Price Target

Biocon Quarterly Results

CAGR Report

Biocon Share holding Pattern

Biocon Share Price Target 2024-2030 Forecast

BIOCON Share Price Target 2025

BIOCON Share Price Target 2026

BIOCON Share Price Target 2027

BIOCON Share Price Target 2028

BIOCON Share Price Target 2029

BIOCON Share Price Target 2030

Official Website – biocon.com